Loading...
Market
Story
Moderna Reports Surprise Q3 Profit with $1.86B Revenue, $1.8B COVID-19 Vaccine Sales
Nov 7, 2024, 11:42 AM
Moderna Inc. reported its third-quarter 2024 financial results, revealing a surprise profit driven by cost-cutting measures and higher-than-expected sales of its COVID-19 vaccine. The company posted revenues of $1.86 billion, surpassing the estimated $1.25 billion. COVID-19 vaccine revenue alone accounted for $1.8 billion, beating the $1.2 billion estimate. Moderna's GAAP net income was $13 million, a significant turnaround from a net loss of $3.6 billion year-over-year. The company also reported cash and cash equivalents of $1.64 billion, below the estimated $2.93 billion. Despite low revenue from its new respiratory syncytial virus (RSV) shot, Moderna reiterated its full-year 2024 product sales forecast of $3.0 to $3.5 billion. Spikevax sales for the quarter were $1.8 billion, and the company reported total cash and cash equivalents of $9.2 billion.
View original story
Similar markets
Negative EPS • 25%
$0.00 to $0.50 • 25%
$0.51 to $1.00 • 25%
More than $1.00 • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
Outperforms S&P 500 • 25%
Matches S&P 500 • 25%
Underperforms S&P 500 • 25%
Declines • 25%
COVID-19 vaccines • 25%
RSV vaccines • 25%
Other vaccines • 25%
Non-vaccine products • 25%
Decrease by more than 10% • 25%
Change between -10% and 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%